GLP1R and atherosclerosis: The data above provided a sound rationale for the delivery of a GLP-1R agonist Lira as an intervention in atherosclerosis with the goal of targeting cholesterol-loaded smooth muscle cells to effectively prevent smooth muscle-to-macrophage transition.